| Literature DB >> 35514141 |
Michael D Swartz1, Stacia M DeSantis1, Ashraf Yaseen1, Frances A Brito1, Melissa A Valerio-Shewmaker2, Sarah E Messiah3, Luis G Leon-Novelo1, Harold W Kohl4,5, Cesar L Pinzon-Gomez1, Tianyao Hao1, Shiming Zhang1, Yashar Talebi1, Joy Yoo1, Jessica R Ross1, Michael O Gonzalez1, Leqing Wu1, Steven H Kelder4, Mark Silberman6, Samantha Tuzo6, Stephen J Pont7, Jennifer A Shuford7, David Lakey8, Eric Boerwinkle1.
Abstract
Understanding the duration of antibodies to the SARS-CoV-2 virus that causes COVID-19 is important to controlling the current pandemic. Participants from the Texas Coronavirus Antibody REsponse Survey (Texas CARES) with at least one nucleocapsid protein antibody test were selected for a longitudinal analysis of antibody duration. A linear mixed model was fit to data from participants (n= 4,553) with one to three antibody tests over 11 months (10/1/2020-9/16/2021), and models fit showed that expected antibody response after COVID-19 infection robustly increases for 100 days post-infection, and predicts individuals may remain antibody positive from natural infection beyond 500 days, depending on age, body mass index, smoking or vaping use, and disease severity (hospitalized or not; symptomatic or not).Entities:
Keywords: Antibodies; Antibody Duration; COVID-19; SARS-CoV-2
Year: 2022 PMID： 35514141 DOI： 10.1093/infdis/jiac167
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226